Finasteride Tablet, Film Coated
Product Images NDC 68071-3234

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68071-3234). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 3234 9

This is a description of a pharmaceutical product called "Finasteride" that comes in a 5mg strength. It has a Lot # 00000 and an expiration date of "00-00". It is advised to call a doctor for any side effects and to store it at a controlled temperature of 68-77°F. There is a warning message stating to keep it out of reach of children. The manufacturer's NDC code is 65862-149-90 and the product's NDC code is 68071-3234-09. It is not clear what the product is used for, other than it may relate to pain relief.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

This appears to be a table or graph showing the mean change in symptom score over a period of 4 years in two long-term efficacy and safety studies of a drug (possibly finasteride) compared to a placebo treatment. The table includes specific data points at the baseline and each year, as well as a significant figure labeled "1 SE". Without further context or information, it is difficult to provide a more detailed or specific description.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

This appears to be a figure (Figure 2) showing the percent of patients having surgery for BPH (benign prostatic hyperplasia), including TURP (transurethral resection of prostate), with placebo and Finasteride treatments. The observation time is in months, and there are two groups - a Placebo Group and a Finasteride Group. The figure shows the number of events and the number at risk per year for each group.*

FDA Label Image

Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Finasteride Fig3)

The text describes a figure (Figure4) that shows the mean percent change from baseline and 1 SE in prostate volume over 4 years, in a long-term efficacy and safety study with a placebo group (n=155) and a group receiving finasteride treatment (n=157). The table shows the baseline, and the volume in year 1, year 2, year 3, and year 4 for both groups.*

FDA Label Image

Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Finasteride Fig4)

The text describes a figure (Figure 5) showing the percentage of people who experienced a 4-point increase in their AUA symptom score over time (up to 55 years from randomization) for different treatment groups. The data is represented in a cumulative incidence graph, with treatment groups plotted against the years from randomization.*

FDA Label Image

Chemical Structure (Finasteride Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.